Clinical trial
An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy
NCT00363974 is registered in ClinicalTrials.gov with Aegera Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy
- Lead sponsor
- Aegera Therapeutics
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2005
- Completion date
- March 31, 2009
- Enrollment
- 54 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.